Spots Global Cancer Trial Database for A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients

Official Title: A Phase I Study of ABT-888 in Combination With Temozolomide (TMZ) in Subjects With Non-Hematologic Malignancies (NHM) and Metastatic Melanoma (MM)

Study ID: NCT00526617

Conditions

Non-hematologic Malignancies

Metastatic Melanoma

Breast Cancer

Ovarian Cancer

Primary Peritoneal Cancer

Fallopian Tube Cancer

Hepatocellular Carcinoma

Interventions

ABT-888

Temozolomide

Study Description

Brief Summary: This Phase I clinical trial is studying the side effects and best dose of ABT-888 when given together with Temozolomide (chemotherapy) in treating patients with solid tumors, including metastatic melanoma (MM), BRCA deficient breast, ovarian, primary peritoneal, or fallopian tube cancer, and hepatocellular carcinoma (HCC).

Detailed Description: A Phase 1, multicenter, dose-escalation study evaluating the safety and tolerability of the PARP inhibitor ABT-888 in combination with Temozolomide (TMZ) in subjects with non-hematologic malignancies (NHM), including metastatic melanoma (MM), BRCA deficient breast, ovarian, primary peritoneal, or fallopian tube cancer, and hepatocellular carcinoma (HCC).